D-Pharm (TASE: DPRM) discovers and develops lipid-based drugs for the treatment of central nervous system disorders and cancer. The Company has developed two unique platform technologies that generate lipid–like medicines which utilize lipid specific properties and lipid-related pathways in living cells. The company's lead product is DP-b99 for treatment of Acute Stroke.

Gamida Cell is the most advanced stem cells company worldwide. It is developing cell therapies based on expanded stem cells for the treatment of such illnesses as blood cancers, cardiac disease and neurological disorders.

NiTi is developing, manufacturing and marketing a portfolio of FDA/CE approved nitinol alloy based devices for the multi-billion dollar GI surgery, interventional endoscopy and NOTES markets.

PetNovations' mission statement is to revolutionize the current "low-tech" pet equipment market. The company is developing, manufacturing and marketing products that improve the life quality of pets and pet owners by introducing advanced, new-concept solutions to pet owners' most basic unmet needs.

HomeSkinovations develops, manufactures and sells advanced home-use aesthetic devices. The company’s patent pending Home Pulsed Light™ technology (HPL™) brings nearly two decades of advancements in light and laser technology together in a pulsed-light system designed exclusively for safe and effective aesthetic treatments at home.

EasyGlide is developing a disposable add-on to a standard colonoscope which enhances cleaning capabilities and allows superior stool evacuation capabilities during procedure.

EasyLap's mission is to develop supporting, easy to use devices, which will simplify and shorten laparoscopic procedures, thus enabling more widespread use of this superior, yet not exploited, surgical technique.

SunSoul is developing, manufacturing and marketing outdoor clothing with therapeutic and cosmetic impact on the skin, based on the well known fact that specific wavelengths of sunlight have these effects.

Invasix develops a line of devices for semi-invasive cosmetic surgery for core aesthetic physicians. The company's proprietary technology will enable physicians to broaden their offering to potential patients, and deliver better results in shorter and simpler procedures.

Metamorefix is developing new dermal fillers based on a biocompatible and biodegradable material for aesthetic volume rejuvenation and soft tissue augmentation.

Peri-Ness is a biotechnology company focusing on addressing the problem of male infertility. The company’s product is a systemic protein-based drug for treatment of male sub-fertility.

Spirocor has advanced significant coronary artery disease (S-CAD) diagnosis by developing an office based, effective, low-cost, low-risk, non-invasive, functional diagnostic test assessing cardiovascular respiratory response. This web based platform, via its secure electronic access, enables cardiologists throughout the world to evaluate and fast track the diagnosis and treatment of S-CAD.